1/16
11:51 am
mrk
JPM26: Dealmaking optimism at JPM 2026 despite absence of mega-M&As [Yahoo! Finance]
Low
Report
JPM26: Dealmaking optimism at JPM 2026 despite absence of mega-M&As [Yahoo! Finance]
1/15
09:09 am
mrk
Is Merck Stock A Trap At $110? [Forbes]
Low
Report
Is Merck Stock A Trap At $110? [Forbes]
1/15
07:30 am
mrk
Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade [Yahoo! Finance Canada]
Low
Report
Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade [Yahoo! Finance Canada]
1/15
07:27 am
mrk
Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade [Yahoo! Finance]
Low
Report
Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade [Yahoo! Finance]
1/14
11:11 am
mrk
Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings? [Yahoo! Finance]
Low
Report
Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings? [Yahoo! Finance]
1/14
09:21 am
mrk
Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma [Yahoo! Finance]
Low
Report
Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma [Yahoo! Finance]
1/13
07:07 pm
mrk
7MM Insomnia Market Opportunity Assessment and Forecast Report 2022-2025 & 2025-2032 [Yahoo! Finance]
Low
Report
7MM Insomnia Market Opportunity Assessment and Forecast Report 2022-2025 & 2025-2032 [Yahoo! Finance]
1/13
01:56 pm
mrk
Merck Lifts Long-Term Revenue Target [Yahoo! Finance]
Low
Report
Merck Lifts Long-Term Revenue Target [Yahoo! Finance]
1/13
08:56 am
mrk
JPM26: MSD homes in on derisking strategy amid Keytruda patent cliff [Yahoo! Finance]
Low
Report
JPM26: MSD homes in on derisking strategy amid Keytruda patent cliff [Yahoo! Finance]
1/13
05:44 am
mrk
Merck & Co., Inc. (NYSE:MRK) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Merck & Co., Inc. (NYSE:MRK) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/12
06:07 pm
mrk
JPM26: US biotech's ‘Sputnik moment,' Pfizer's obesity ambitions and Bristol Myers' big year [Yahoo! Finance]
Low
Report
JPM26: US biotech's ‘Sputnik moment,' Pfizer's obesity ambitions and Bristol Myers' big year [Yahoo! Finance]
1/12
10:00 am
mrk
Healthcare Leader Fred Hassan Appointed Executive Chair of Norstella
Low
Report
Healthcare Leader Fred Hassan Appointed Executive Chair of Norstella
1/12
07:05 am
mrk
1 Momentum Stock Worth Your Attention and 2 Facing Headwinds [Yahoo! Finance]
Low
Report
1 Momentum Stock Worth Your Attention and 2 Facing Headwinds [Yahoo! Finance]
1/12
06:19 am
mrk
Cancer Drugs Drive Nearly One-Fifth Of Pharma Sales [zero hedge]
Low
Report
Cancer Drugs Drive Nearly One-Fifth Of Pharma Sales [zero hedge]
1/12
03:33 am
mrk
3 Dividend Stocks to Hold for the Next 10 Years [Yahoo! Finance]
Low
Report
3 Dividend Stocks to Hold for the Next 10 Years [Yahoo! Finance]
1/10
01:31 am
mrk
Wells Fargo Adds Merck (MRK) to Q1 2026 Tactical List Ahead of Key Catalysts [Yahoo! Finance]
Low
Report
Wells Fargo Adds Merck (MRK) to Q1 2026 Tactical List Ahead of Key Catalysts [Yahoo! Finance]
1/8
11:32 am
mrk
Merck rises as Wolfe upgrades to Outperform; AbbVie downgraded [Seeking Alpha]
Low
Report
Merck rises as Wolfe upgrades to Outperform; AbbVie downgraded [Seeking Alpha]
1/8
09:23 am
mrk
Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked in - Wolfe [Yahoo! Finance]
Low
Report
Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked in - Wolfe [Yahoo! Finance]
1/8
08:02 am
mrk
Merck & Co., Inc. (NYSE:MRK) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $135.00 price target on the stock.
Low
Report
Merck & Co., Inc. (NYSE:MRK) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $135.00 price target on the stock.
1/8
06:38 am
mrk
Diagonal banks another $125M for ‘clustering' antibody drugs [Yahoo! Finance]
Low
Report
Diagonal banks another $125M for ‘clustering' antibody drugs [Yahoo! Finance]
1/7
03:22 pm
mrk
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at UBS Group AG from $105.00 to $130.00. They now have a "buy" rating on the stock.
Low
Report
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at UBS Group AG from $105.00 to $130.00. They now have a "buy" rating on the stock.
1/7
02:55 pm
mrk
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Citigroup Inc. from $95.00 to $110.00. They now have a "neutral" rating on the stock.
Low
Report
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Citigroup Inc. from $95.00 to $110.00. They now have a "neutral" rating on the stock.
1/7
08:10 am
mrk
Egle Therapeutics Appoints John Celebi as Chief Executive Officer [Yahoo! Finance]
Low
Report
Egle Therapeutics Appoints John Celebi as Chief Executive Officer [Yahoo! Finance]
1/7
07:21 am
mrk
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC [Yahoo! Fi
Low
Report
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC [Yahoo! Fi
1/7
07:03 am
mrk
Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3 [Yahoo! Finance]
Low
Report
Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3 [Yahoo! Finance]